Liver transplantation: Yesterday, today and tomorrow

被引：10

作者：

Osman Abbasoglu

机构：

[1] Department of Surgery Hacettepe University School of Medicine

[2] Sihhiye Ankara 06100 TurkeyAuthor contributions: Abbasoglu O designed research and wrote the paper.

来源：

World Journal of Gastroenterology | 2008年 / 20期

关键词：

Liver transplantation; Hepatitis C virus; Hepatitis B virus; Hepatocellular carcinoma; ABO incompatibility; Living donor;

D O I：

暂无

中图分类号：

R657.3 [肝及肝管];

学科分类号：

1002 ; 100210 ;

摘要：

With the advances in technical skills, management of postoperative complications and improvements in immunosuppressive drugs, liver transplantation is the standard treatment for many patients with chronic liver disease. Today, shortage of donor organs seems to be the major limiting factor for the application of liver transplantation. This review focuses on five issues that are challenging to clinical practice of liver transplantation and relevant to gastroenterologists. These include living donor liver transplantation, recurrent viral hepatitis, non-heart-beating donors, hepatocellular carcinoma, and ABO incompatible liver transplantation. Living donor and non-heart beating donor transplantations were initiated as a solution to increase the donor organ pool and it is expected that there will be an increase in the number of these donors. Recurrent hepatitis C and hepatocellular carcinoma following liver transplantation are among major problems and ongoing research in these diseases may lead to better outcomes in these recipients.

引用

页码：3117 / 3122

页数：6

共 25 条

[1]

Surgical Treatment of Hepatocellular Carcinoma beyond Milan Criteria. Results of Liver Resection, Salvage Transplantation, and Primary Liver Transplantation[J] . Marcelo E. Facciuto,Baburao Koneru,Juan P. Rocca,David C. Wolf,Leona Kim-Schluger,Paul Visintainer,Kenneth M. Klein,Hoo Chun,Michael Marvin,Grigory Rozenblit,Manuel Rodriguez-Davalos,Patricia A. Sheiner.Annals of Surgical Oncology . 2008 (5)

[2]

＜ce:link locator="fx1"/＞ Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation[J] . Edward J. Gane,Peter W. Angus,Simone Strasser,Darrell H.G. Crawford,John Ring,Gary P. Jeffrey,Geoffrey W. McCaughan.Gastroenterology . 2007 (3)

[3] Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation [J].

Takaki, Akinobu ;

Yagi, Takahito ;

Iwasaki, Yoshiaki ;

Sadamori, Hiroshi ;

Matsukawa, Hiroyoshi ;

Matsuda, Hiroaki ;

Shinoura, Susumu ;

Umeda, Yuuzou ;

Miyake, Yasuhiro ;

Terada, Ryou ;

Kobashi, Haruhiko ;

Sakaguchi, Kohsaku ;

Tanaka, Noriaki ;

Shiratori, Yasushi .

TRANSPLANTATION, 2007, 83 (02) :231-233

[4]

Early recurrence of hepatitis C virus infection after liver transplantation[J] . Lydia M. Petrovic.Liver Transpl . 2006 (S2)

[5] Living-donor liver transplantation for hepatocellular carcinoma [J].

Furukawa, Hiroyuki ;

Shimamura, Tsuyoshi ;

Suzuki, Tomomi ;

Taniguchi, Masahiko ;

Yamashita, Kenichiro ;

Kamiyama, Toshiya ;

Matsushita, Michiaki ;

Todo, Satoru .

JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2006, 13 (05) :393-397

[6]

Pediatric liver transplantation: Past, present, and future[J] . Benjamin L. Shneider,Sukru Emre.Liver Transpl . 2006 (4)

[7]

Liver transplantation from non–heart‐beating donors: Current status and future prospects[J] . Srikanth Reddy,Miguel Zilvetti,Jens Brockmann,Andrew McLaren,Peter Friend.Liver Transpl . 2004 (10)

[8] Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States [J].